Drugs / MBRC-101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06014658 | Nov 2023 → Jul 2026 overdue | cancer | MBrace Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MBRC-101 | “Here, we report the design and preclinical evaluation of MBRC-101, a first-in-class antibody-drug conjugate (ADC) targeting EphA5, a receptor tyrosine kinase with an...” PMID 40662373 ↗ Jul 2025 |
| Target | EPHA5 | “MBRC-101, a first-in-class antibody-drug conjugate (ADC) targeting EphA5” PMID 40662373 ↗ Jul 2025 |